Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Neal

Showing results (431-440 of 484) with videos related to

Pageof 49
Sort By:
Diabetes, Obesity & Metabolism|March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
The Lancet. Neurology|April 9, 2008
Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trialCraig S Anderson, Yining Huang, Ji Guang Wang, et al.
The New England Journal of Medicine|June 10, 2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, Anushka Patel, Stephen MacMahon, et al.
Lancet (London, England)|February 14, 2017
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic reviewClara K Chow, Jay Thakkar, Alex Bennett, et al.
JAMA Network Open|December 8, 2021
Factors Associated With the Use of a Salt Substitute in Rural ChinaYishu Liu, Hongling Chu, Ke Peng, et al.
Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
BMJ Open|July 21, 2021
Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)Ka-Chun Li, Maoyi Tian, Bruce Neal, et al.
Pageof 49

Showing results (431-440 of 484) with videos related to

Sort By:
Pageof 49
Diabetes, Obesity & Metabolism|March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
The Lancet. Neurology|April 9, 2008
Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trialCraig S Anderson, Yining Huang, Ji Guang Wang, et al.
The New England Journal of Medicine|June 10, 2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, Anushka Patel, Stephen MacMahon, et al.
Lancet (London, England)|February 14, 2017
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic reviewClara K Chow, Jay Thakkar, Alex Bennett, et al.
JAMA Network Open|December 8, 2021
Factors Associated With the Use of a Salt Substitute in Rural ChinaYishu Liu, Hongling Chu, Ke Peng, et al.
Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
BMJ Open|July 21, 2021
Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)Ka-Chun Li, Maoyi Tian, Bruce Neal, et al.
Pageof 49